Financial Assistance
Carrying the financial load of cancer care can be stressful at times. As part of the care team, Caris Life Sciences® is dedicated to ensuring that every cancer patient has access to the best possible treatment.
Patient Financial Burden
While most insurance plans cover Caris molecular testing, we have additional financial assistance programs that provide added financial flexibility for patients. Caris’ Compassionate Care Program assists uninsured patients who may not be able to afford out-of-pocket costs associated with our molecular profiling test.
Insurance Coverage
Caris Molecular Intelligence® typically is reimbursed by insurance providers, as well as Medicare. The cost will differ among the various Caris Molecular Intelligence offerings, depending on the tumor profile offered, and the number of biomarkers analyzed and technologies used. We will perform the services ordered and deemed medically necessary by a physician, regardless of our network status.
Reading Your Reports
Caris Molecular Intelligence performs thorough molecular testing on DNA, RNA and proteins to identify the biomarkers driving a patient’s tumor, and to compare the biomarkers with data from clinical studies around the world. Here’s how the process works:
1
Sample sent to Caris
The ordering clinician collects and sends a tissue sample to Caris
2
Biomarker Testing
Comprehensive testing on DNA, RNA and proteins is performed at our state-of-the-art, 66,000 sq. ft. laboratory
3
Bioinformatics Performed
Team interprets the data using thousands of relevant clinical papers to match your tumor’s biomarkers to treatment options
4
Report Generated
Results are returned in approximately 10-14 days in an online and easy-to-understand format
5
Physician Reviews Report
Profiling reveals the molecular blueprint to help guide precise treatment decisions
Complete Molecular Intelligence Report
The MI Profile™ Report delivers high impact results, including potentially relevant, actionable clinical information, in an easy-to-interpret format. Every report includes access to the MI Portal and the Clinical Trials Connector™, which matches each patient’s unique biomarker expression profile to open, pertinent, clinical trial opportunities.
